- Home
- JWEL vs APVO Comparison
JWEL vs APVO Comparison
Compare JWEL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- APVO
- Stock Information
- Founded
- JWEL 2012
- APVO 2016
- Country
- JWEL China
- APVO United States
- Employees
- JWEL N/A
- APVO N/A
- Industry
- JWEL Other Consumer Services
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- APVO Health Care
- Exchange
- JWEL Nasdaq
- APVO Nasdaq
- Market Cap
- JWEL 4.1M
- APVO 4.4M
- IPO Year
- JWEL 2021
- APVO N/A
- Fundamental
- Price
- JWEL $2.43
- APVO $4.50
- Analyst Decision
- JWEL
- APVO Strong Buy
- Analyst Count
- JWEL 0
- APVO 1
- Target Price
- JWEL N/A
- APVO $296.00
- AVG Volume (30 Days)
- JWEL 881.8K
- APVO 485.4K
- Earning Date
- JWEL 12-27-2024
- APVO 11-07-2024
- Dividend Yield
- JWEL N/A
- APVO N/A
- EPS Growth
- JWEL N/A
- APVO N/A
- EPS
- JWEL N/A
- APVO N/A
- Revenue
- JWEL $160,009,293.00
- APVO N/A
- Revenue This Year
- JWEL N/A
- APVO N/A
- Revenue Next Year
- JWEL N/A
- APVO N/A
- P/E Ratio
- JWEL N/A
- APVO N/A
- Revenue Growth
- JWEL N/A
- APVO N/A
- 52 Week Low
- JWEL $1.00
- APVO $3.65
- 52 Week High
- JWEL $3.71
- APVO $399.60
- Technical
- Relative Strength Index (RSI)
- JWEL 44.78
- APVO 35.34
- Support Level
- JWEL $2.45
- APVO $3.65
- Resistance Level
- JWEL $3.13
- APVO $4.78
- Average True Range (ATR)
- JWEL 0.36
- APVO 1.95
- MACD
- JWEL -0.11
- APVO -0.70
- Stochastic Oscillator
- JWEL 3.67
- APVO 7.55
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.